Medicare can pay for obesity drugs like Wegovy in certain heart patients
Time:2024-05-22 02:49:41 Source:businessViews(143)
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Previous:Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
Next:Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
You may also like
- Patrick Reed withdraws from US Open qualifying and ends streak of playing the majors
- Collin Morikawa part of 4
- An Alabama prison warden is arrested on drug charges
- The 12 jurors picked in Trump's hush money trial, including a woman who called him 'selfish'
- A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
- 'Bluey' hits the mark with children and adults alike
- Bill Tobin, a longtime NFL executive who helped build the 1985 Bears championship team, has died
- Coyotes' move to Salt Lake City elicits opposing responses in 2 cities
- Colin Jost left red